This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock RTRX vs. RNA, OGN, ZLAB, PRGO, RARE, AKRO, RYTM, MRUS, VKTX, and PTGXShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Avidity Biosciences (RNA), Organon & Co. (OGN), Zai Lab (ZLAB), Perrigo (PRGO), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Merus (MRUS), Viking Therapeutics (VKTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "medical" sector. Travere Therapeutics vs. Avidity Biosciences Organon & Co. Zai Lab Perrigo Ultragenyx Pharmaceutical Akero Therapeutics Rhythm Pharmaceuticals Merus Viking Therapeutics Protagonist Therapeutics Avidity Biosciences (NASDAQ:RNA) and Travere Therapeutics (NASDAQ:RTRX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Do analysts recommend RNA or RTRX? Avidity Biosciences presently has a consensus price target of $66.69, suggesting a potential upside of 149.41%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Travere Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to RNA or RTRX? In the previous week, Avidity Biosciences had 7 more articles in the media than Travere Therapeutics. MarketBeat recorded 8 mentions for Avidity Biosciences and 1 mentions for Travere Therapeutics. Avidity Biosciences' average media sentiment score of 1.06 beat Travere Therapeutics' score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, RNA or RTRX? Avidity Biosciences has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Which has better valuation and earnings, RNA or RTRX? Travere Therapeutics has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.90M294.99-$212.22M-$2.89-9.25Travere Therapeutics$175.34M5.08-$146.43M-$3.46-5.04 Does the MarketBeat Community believe in RNA or RTRX? Travere Therapeutics received 253 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 73.17% of users gave Travere Therapeutics an outperform vote while only 69.01% of users gave Avidity Biosciences an outperform vote. CompanyUnderperformOutperformAvidity BiosciencesOutperform Votes16769.01% Underperform Votes7530.99% Travere TherapeuticsOutperform Votes42073.17% Underperform Votes15426.83% Is RNA or RTRX more profitable? Travere Therapeutics has a net margin of -49.13% compared to Avidity Biosciences' net margin of -2,772.45%. Avidity Biosciences' return on equity of -27.66% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-2,772.45% -27.66% -24.56% Travere Therapeutics -49.13%-36.38%-14.90% SummaryAvidity Biosciences beats Travere Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$890.35M$6.76B$5.55B$7.86BDividend YieldN/A2.81%5.35%4.04%P/E Ratio-8.277.0923.4218.67Price / Sales5.08199.58364.8587.31Price / CashN/A65.6738.1634.64Price / Book3.395.966.624.09Net Income-$146.43M$142.11M$3.20B$246.93M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$17.44-2.7%N/A+145.1%$890.35M$175.34M-8.27221News CoverageHigh Trading VolumeRNAAvidity Biosciences2.5385 of 5 stars$33.30+8.0%$66.69+100.3%+1.3%$4.00B$10.90M-11.56190OGNOrganon & Co.4.7983 of 5 stars$15.35-0.3%$20.80+35.5%-23.7%$3.96B$6.40B4.6110,000News CoveragePositive NewsZLABZai Lab2.18 of 5 stars$35.67+1.7%$47.37+32.8%+123.0%$3.91B$398.99M-12.881,950Gap UpPRGOPerrigo4.8183 of 5 stars$27.73-0.7%$33.00+19.0%-13.8%$3.81B$4.37B-23.708,900Short Interest ↓News CoveragePositive NewsRAREUltragenyx Pharmaceutical4.4148 of 5 stars$39.36+0.5%$91.71+133.0%-28.0%$3.64B$560.23M-6.211,276AKROAkero Therapeutics4.2408 of 5 stars$45.08-0.3%$76.29+69.2%+60.5%$3.59BN/A-12.0230RYTMRhythm Pharmaceuticals4.4154 of 5 stars$53.72+3.2%$69.46+29.3%+17.2%$3.40B$130.13M-12.41140MRUSMerus2.3318 of 5 stars$48.77+3.2%$85.31+74.9%-12.1%$3.37B$36.13M-12.3537News CoverageVKTXViking Therapeutics4.2271 of 5 stars$29.28+1.1%$97.67+233.6%-69.9%$3.29BN/A-29.2820Options VolumePTGXProtagonist Therapeutics3.6025 of 5 stars$52.53-0.2%$62.56+19.1%+65.8%$3.22B$434.43M19.75120Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Avidity Biosciences Alternatives Organon & Co. Alternatives Zai Lab Alternatives Perrigo Alternatives Ultragenyx Pharmaceutical Alternatives Akero Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Merus Alternatives Viking Therapeutics Alternatives Protagonist Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTRX) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RTRX Stock Free RTRX Stock Alerts